CSE: SONA | OTCQB: SNANF
   +1-902-442-0653   Purdy’s Wharf Tower II Suite 2001 – 1969 Upper Water Street

Category: News Releases

News & Media — News Releases

News Releases

Sona Nanotech Reports 80% Response Rate in First-In-Human Tht Cancer Therapy Study
October 19, 2025

Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
Sona Nanotech to Host Investor Webinar to Discuss Clinical Study
October 17, 2025

Sona Nanotech to Host Investor Webinar to Discuss Clinical Study
Sona Provides Update on First-In-Human Clinical Trial
August 25, 2025

Sona Provides Update on First-In-Human Clinical Trial
Sona Announces Canadian Melanoma Clinical ‘Pilot’ Study Ethics Approval
July 23, 2025

Sona Announces Canadian Melanoma Clinical ‘Pilot’ Study Ethics Approval
_First Patient Dosed in Early Feasibility Study Trial of Its Cancer Therapy
July 7, 2025

First Patient Dosed in Early Feasibility Study Trial of Its Cancer Therapy
Sona Announces Ethics Committee Approval For Melanoma Clinical Trial
June 27, 2025

Sona Announces Ethics Committee Approval For Melanoma Clinical Trial
Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy
June 16, 2025

Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy
Sona Successfully Completes FDA-required Toxicity Study
May 27, 2025

Sona Successfully Completes FDA-required Toxicity Study
Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial
May 15, 2025

Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial
BioVaxys and Sona Nanotech Enter Research Collaboration
May 7, 2025

BioVaxys and Sona Nanotech Enter Research Collaboration
Load More
Subscribe